Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings
On track for full data read out in the first half of 2026
You might also be interested in reading SEC Warns FTX Over Legality of Crypto Asset Distribution in Chapter 11 Plan.